CU23318A7 - Composiciones farmacã0/00uticas de la tizoxanida y nitazoxanida - Google Patents

Composiciones farmacã0/00uticas de la tizoxanida y nitazoxanida

Info

Publication number
CU23318A7
CU23318A7 CU20030074A CU20030074A CU23318A7 CU 23318 A7 CU23318 A7 CU 23318A7 CU 20030074 A CU20030074 A CU 20030074A CU 20030074 A CU20030074 A CU 20030074A CU 23318 A7 CU23318 A7 CU 23318A7
Authority
CU
Cuba
Prior art keywords
particle size
compositions
tizoxanida
nitazoxanida
farmacã0
Prior art date
Application number
CU20030074A
Other languages
English (en)
Inventor
Jean-Francois Rossignol
Original Assignee
Romark Lab Lc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/887,810 external-priority patent/US5856348A/en
Application filed by Romark Lab Lc filed Critical Romark Lab Lc
Publication of CU23318A7 publication Critical patent/CU23318A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que contiene como agente activo por lo menos un compuesto seleccionado del grupo integrado por la fórmula I y la fórmula II. El agente activo tiene preferentemente la forma de partículas con un tamaÅ"o de partícula menor que 200 micrometros y un tamaÅ"o medio de partícula mayor que 10 micrometros. De manera preferente, las composiciones farmacéuticas están estabilizadas con por lo menos un ácido farmacéuticamente aceptable. Las composiciones farmacéuticas de la presente invención son útiles para el tratamiento de infecciones oportunistas en personas con el sistema inmune comprometido o suprimido, así como en el tratamiento de infecciones por tremátodos.</P>
CU20030074A 1997-05-07 2003-04-03 Composiciones farmacã0/00uticas de la tizoxanida y nitazoxanida CU23318A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/852,447 US5968961A (en) 1997-05-07 1997-05-07 Pharmaceutical compositions of tizoxanide and nitazoxanide
US08/887,810 US5856348A (en) 1994-09-08 1997-07-03 Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide

Publications (1)

Publication Number Publication Date
CU23318A7 true CU23318A7 (es) 2008-10-22

Family

ID=25313357

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20030074A CU23318A7 (es) 1997-05-07 2003-04-03 Composiciones farmacã0/00uticas de la tizoxanida y nitazoxanida

Country Status (12)

Country Link
US (2) US5968961A (es)
AR (1) AR008355A1 (es)
BG (1) BG65679B1 (es)
CO (1) CO4950538A1 (es)
CU (1) CU23318A7 (es)
ID (1) ID24828A (es)
LT (1) LT4751B (es)
PL (1) PL193556B1 (es)
PY (1) PY0000172A (es)
RO (1) RO122247B1 (es)
RS (2) RS49831B (es)
ZA (1) ZA983849B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125568B2 (en) * 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
CA2467321A1 (en) * 2004-05-14 2005-11-14 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
UA90864C2 (en) * 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
AU2006235490A1 (en) * 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
MX2008008723A (es) * 2006-01-09 2008-09-26 Romark Lab Lc Tratamiento de la hepatitis viral.
MX381895B (es) 2009-02-13 2025-03-13 Romark Laboratories Lc Formulaciones farmaceuticas de liberacion controlada de nitazoxanida.
CN105853415A (zh) 2009-05-12 2016-08-17 罗马克实验室有限公司 卤代烷基杂芳基苯甲酰胺化合物
BRPI1014322A2 (pt) 2009-06-26 2015-08-25 Romark Lab Lc Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
CN107096032A (zh) 2011-05-16 2017-08-29 罗马克实验室有限公司 在有需要的对象中刺激免疫应答的方法
US9498441B2 (en) * 2012-01-27 2016-11-22 Siegfried Rhein S.A. De C.V. Nitazoxadine composition and process to prepare same
US20140306689A1 (en) 2013-04-10 2014-10-16 Texas Instruments, Incorporated High resolution current pulse analog measurement
JP6633092B2 (ja) 2014-11-11 2020-01-22 ロマーク ラボラトリーズ，リミティド カンパニー チゾキサニド、その類似体又は塩のプロドラッグを用いる組成物及び治療方法
HK1250945A1 (zh) 2016-03-31 2019-01-18 罗马克实验室有限公司 用於治疗病毒性感染的噻唑化物化合物
SI3442580T1 (sl) 2016-04-11 2021-01-29 Genfit Metode zdravljenja holestatičnih in fibrotičnih bolezni
US11173149B2 (en) 2017-04-18 2021-11-16 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase A3
EP3740494A4 (en) 2018-02-02 2021-11-03 Ripple Therapeutics Corporation GLASS FORMULATIONS WITH STEROID DIMERS AND USES THEREOF
WO2019241376A1 (en) 2018-06-14 2019-12-19 The Trustees Of Columbia University In The City Of New York Treatment of cognitive disorders using nitazoxanide (ntz), nitazoxanide (ntz) analogs, and metabolites thereof
WO2020154815A1 (en) 2019-02-01 2020-08-06 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof
US12509469B2 (en) 2019-08-07 2025-12-30 Ripple Therapeutics Corporation Compositions and methods for the treatment of pain and dependence disorders
CA3176134A1 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
JP2023537237A (ja) 2020-07-20 2023-08-31 ロマーク ラボラトリーズ，リミティド カンパニー チゾキサニドおよび２－ヒドロキシ－ｎ－（５－クロロ－１，３－チアゾル－２－イル）ベンズアミド（ｒｍ－４８４８）とエタノールアミン、モルホリン、プロパノールアミン、ピペラジン、およびｎ－メチルピペラジンの結晶塩
IL300801A (en) 2020-08-24 2023-04-01 Romark Laboratories Lc Use of thiazolides against the corona virus
US20240417381A1 (en) 2021-10-05 2024-12-19 Council Of Scientific And Industrial Research An Indian Registered Body Incorporated An improved process for the preparation of nitazoxanide and intermediates thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
US4315018A (en) * 1978-12-07 1982-02-09 Rossignol Jean F Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
US5496809A (en) * 1989-05-10 1996-03-05 Bristol-Myers Squibb Co Stable solutions of rebeccamycin analog
US5387598A (en) * 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
SI0755386T1 (en) 1994-04-13 2002-10-31 Romark Laboratories, L.C. Benzamide derivative, compositions containing said derivative and use thereof
US5578621A (en) * 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives

Also Published As

Publication number Publication date
PY0000172A (es) 2001-12-03
LT99141A (lt) 2000-08-25
RS50046B (sr) 2008-11-28
US6117894A (en) 2000-09-12
LT4751B (lt) 2001-01-25
US5968961A (en) 1999-10-19
BG65679B1 (bg) 2009-06-30
ZA983849B (en) 1999-08-27
RS20070379A (sr) 2008-06-05
RS49831B (sr) 2008-08-07
CO4950538A1 (es) 2000-09-01
ID24828A (id) 2000-08-24
PL193556B1 (pl) 2007-02-28
YU57199A (es) 2002-08-12
AR008355A1 (es) 2000-01-19
RO122247B1 (ro) 2009-03-30

Similar Documents

Publication Publication Date Title
PY0000172A (es) Composiciones farmaceuticas de la tizoxanida y la nitazoxanida
CO4810223A1 (es) Composiciones de champu estilizantes
BR0111126A (pt) Derivados de aminoácidos cìclicos úteis como agentes farmacêuticos
ES2187467T3 (es) Composiciones liquidas de proteccion solar con buena deposicion y formacion de espuma.
MXPA03006999A (es) Composicion limpiadora espumante suave.
ATE376423T1 (de) Gelierende wässrige pharmazeutische zusammensetzungen
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
AR038575A1 (es) Formulacion oftalmica con nueva composicion de goma
BR9808772A (pt) Composição de vacina multivalente com carreadora misturada
DK1318788T3 (da) Nanopartikulær fastdosissammensætninger
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
BRPI0311716A2 (pt) composição que contém um polímero catiônico com uma alta densidade de carga e um agente condicionador
BRPI0409185A (pt) formulações veterinárias anti-helmìnticas tópicas
DE60108651D1 (de) Wärmegellierende bioabbaubare wässrige polymerlösung
AR078161A1 (es) Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
BR0001468A (pt) ácidos dioxiciclopentil hidroxânicos
AR021624A1 (es) Composiciones para el lavado
CO5140079A1 (es) Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
PE20230514A1 (es) Composiciones farmaceuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
ECSP034915A (es) Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
BRPI0414139A (pt) métodos e composições para tratar infecções por herpes
BR9909121A (pt) Composto, composição farmacêutica, e, processos para inibir a liberação de hormÈnio de luteinização (lh) em um mamìfero em necessidade de tal tratamento e para preparar um composto
DOP2000000091A (es) Composiciones farmaceuticas de la tizoxandia y la nitozoxandia